- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02479464
Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting (HAMM)
May 17, 2019 updated by: Daniel K. Hall-Flavin, Mayo Clinic
A Pilot Study for the Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting
The Mayo Clinic psychiatric pharmacogenomic team has developed a pharmacogenomic algorithm that has been designed to improve the effectiveness and safety of antidepressant medications by providing guidance in medication selection and appropriate dosing.
This algorithm has been incorporated into a new genotyping interpretative report.
This report is now available from AssureRx.
The pharmacogenomic algorithm is based on genotyping both copies of four informative genes.
These four genes are: 1) the Cytochrome P450 2D6 gene; 2) the Cytochrome P450 2C19 gene; 3) the Serotonin Transporter gene (SLC6A4); and 4) the Serotonin 2A receptor gene (5HTR2A).
Though this algorithm is not yet part of the universal standard of care, Mayo clinicians have found it helpful in guiding treatment decisions at Mayo Clinic Rochester.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The proposed pilot study is designed to evaluate the clinical impact of the interpretive report in an outpatient behavioral health clinic in St. Paul, Minnesota.
While the ultimate goal of this project is to show an improvement in patient outcomes, this pilot study will be used to evaluate the feasibility of introducing the pharmacogenomic algorithm to a new setting that does not routinely use the algorithm.
Secondary outcome data will be collected to generate meaningful estimates of the magnitude of potential treatment effects.
The study will consist of two phases, each enrolling 2530 subjects.
In Phase 1, consecutive patients will be prospectively monitored to observe standard practice.
Patients will be given the option to receive genotyping and those that agree will have blood drawn.
However, the results of the genotyping and algorithm will not be released until all phase 1 patients have completed study visits.. Subsequently, in Phase 2, also enrolling 3025 subjects, the results of the genotyping and algorithm will be made available immediately for additional consecutive prospectively monitored patients.
Patients will be prospectively monitored in the same fashion as Phase 1.
The results of the study will be used to perform preliminary analyses and subsequent fully powered multi-site trials will be planned based on the results of this study.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is between the ages of 18 and 80.
- Major depressive disorder or depressive disorder not otherwise specified (NOS) as ascertained by a physician or mental health professional licensed to diagnose.
- Patient is an outpatient and not in imminent need of inpatient hospitalization
- Patient's Hamilton Depression Rating score is >14
- Patient is being seen by a psychiatrist for optimum medication management.
- Ability to read, understand and sign an informed consent document
Exclusion Criteria:
- Serious medical illness (as ascertained via the initial triage screening process)
- Patients with a diagnosis of Bipolar I disorder
- Patients with a diagnosis of Schizophrenia or Schizoaffective disorder
- Patients who are legally unable to consent to enrollment in the study (i.e. patients with legal guardians)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Part 1
This is the treatment as usual arm to monitor the current standard clinical practice
|
|
Other: Part 2
This group will be provided with genotyping results after baseline visit to guide clinical medication management
|
Genotyping results provided in Phase II
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients approached who consent to use of pharmacogenomic algorithm
Time Frame: 8 weeks
|
8 weeks
|
Amount of time from ordering test to receipt of results
Time Frame: 8 weeks
|
8 weeks
|
Proportion of time that the physician prescribed a medication that was recommended by the algorithm
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to remission of depressive symptoms
Time Frame: 8 weeks
|
Hamilton rating of < 7
|
8 weeks
|
Measured side effect burden
Time Frame: 8 weeks
|
Reduction in Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) score.
|
8 weeks
|
Number of participants who change their initial medication regimen
Time Frame: 8 weeks
|
8 weeks
|
|
Health care clinical cost
Time Frame: 8 weeks
|
defined by analysis of mental health resource utilization
|
8 weeks
|
Physician satisfaction with delivery of clinical care
Time Frame: 8 weeks
|
defined by researcher developed Likert-based satisfaction survey
|
8 weeks
|
Patient satisfaction with clinical care
Time Frame: 8 weeks
|
defined by researcher developed Likert-based satisfaction survey
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
June 16, 2015
First Submitted That Met QC Criteria
June 19, 2015
First Posted (Estimate)
June 24, 2015
Study Record Updates
Last Update Posted (Actual)
May 21, 2019
Last Update Submitted That Met QC Criteria
May 17, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-002523
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Genotyping results
-
Mayo ClinicCompleted
-
Mayo ClinicCompletedDepression | Mood Disorder | BipolarUnited States
-
University Hospital, RouenInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Kyungpook National University HospitalCompletedAge-Related Macular DegenerationKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Mayo Clinic; Dana-Farber Cancer Institute; Duke University and other collaboratorsActive, not recruitingLeukemiaUnited States
-
Sohag UniversityNot yet recruiting
-
Sohag UniversityRecruitingType 2 Diabetes MellitusEgypt
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySun Yat-sen UniversityRecruitingPancreatic Cancer | Pharmacokinetics | Gene PolymorphismsChina
-
Istituto Auxologico ItalianoRecruitingPapillary Thyroid CancerItaly
-
Boston UniversityActive, not recruiting